Multiple Myeloma

Introducing the first CAR-T treatment specifically designed for multiple myeloma. By engaging two binding sites, we enhance the durability and efficacy of CAR-T therapy, paving the way for a more robust therapeutic journey.

Our rigorous certification and support systems ensure that as CAR-T innovations evolve, we remain at the forefront of advancing patient care. Together, we’re not just changing the landscape of CAR-T’s…we’re redefining the future of cancer treatment.